HMGB1 and cancer: An anti-HMGB1 antibody or specific inhibitor (i.e. glycyrrhizin) [55] or targeting its proposed receptors (RAGE and the toll-like receptor 4, TLR4) on cancer cells may prevent or inhibit the development of drug resistance.